PURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
|
|
- Julie Carroll
- 8 years ago
- Views:
Transcription
1 COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues - Epivir-HBV (lamivudine); Hepsera (adefovir dipivoxil); Baraclude (entecavir); Tyzeka (telbivudine), and Viread (tenofovir). PURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B. POLICY & COVERAGE: 1. Chronic Hepatitis B with detectable Hepatitis B e Antigen (HBeAg +) Refer to Appendix I for Treatment Algorithm Covered for patients who meet ALL the following criteria: a. Detectable Hepatitis B e Antigen (HBeAg +) detectable Hepatitis B Surface Antigen (HBsAg) for more than 6 months, b. HBV DNA levels 10 5 copies/ml (20,000 IU/ml) by Polymerase Chain Reaction (PCR), c. ALT > 2 times upper limit of normal (ULN) OR moderate/severe hepatitis/significant fibrosis on biopsy. 2. Chronic Hepatitis B with undetectable Hepatitis B e Antigen (HBeAg -) Refer to Appendix II for Treatment Algorithm Covered for patients who meet ALL the following criteria: a. Undetectable Hepatitis B e Antigen (HBeAg -) detectable Hepatitis B Surface Antigen (HBsAg) for more than 6 months, b. HBV DNA levels 10 5 copies/ml (20,000 IU/ml) by PCR assay, OR c. ALT >2 times ULN, OR d. Moderate/severe hepatitis/significant fibrosis on biopsy. 3. Chronic Hepatitis B with Cirrhosis Refer to Appendix III for Treatment Algorithm Covered for patients who meet ALL the following criteria: a. Diagnosed with compensated cirrhosis b. HBV DNA levels > 10 4 copies/ml by PCR assay, OR c. ALT > 2 times upper limit of normal (ULN).
2 DOSING INFORMATION: Drug Name Intron-A Hep B & HBeAg + Indication Hep B & HBeAg - Hep B & Cirrhosis Usual Adult Dose 5 MU a day or 10 MU 3 times/week Usual Pediatric Dose 6 MU/meter 2 TIW (max. 10 MU TIW) Pegasys * * 180 mcg/week t been established Epivir- HBV 100 mg/day 3 mg/kg/day (max. 100mg/day) Hepsera 10 mg/day t been established Tyzeka 600 mg/day t been established Baraclude * * 0.5 mg/day t been established Viread * * 300 mg/day t been established *Clinical guidelines recommend the use these agents for the respective indications. **Abbreviations & tes: Hep B (Chronic Hepatitis B); HBeAg (Hepatitis B Antigen); MU (million units); TIW (three times a week); Intron A (interferon alfa-2b); Pegasys (peginterferon alfa-2a); Epivir-HBV (lamivudine); Hepsera (adefovir dipivoxil); Tyzeka (telbivudine); Baraclude (entecavir), Viread (tenofovir). ***Dose adjustments for Renal insufficient patients may be different (Refer to PI) AUTHORIZATION PERIOD: Intron A (interferon alfa-2b) Initial approval: 16 Weeks Extended approval(pediatric patients): Additional 8 weeks, review of response to interferon therapy is required to determine continuation of therapy beyond 16 weeks. *t approved for chronic hepatitis B adult patients with detectable Hepatitis B e Antigen (HBeAg+) beyond 16 weeks. Pegasys (peginterferon alfa-2a) for chronic hepatitis B with HBeAg positive OR negative Initial approval: 16 Weeks Extended approval: Additional 32 weeks Review of response to interferon therapy is required to determine continuation of therapy beyond 16 weeks. Pegasys is approvable for a MAXIMUM of 48 Weeks te: Interferon therapy is contraindicated in patients who suffer from decompensated liver disease, autoimmune hepatitis or a history of autoimmune disease, and patients who are immunosuppressed transplant recipients. Epivir-HBV (lamivudine), Hepsera (adefovir dipivoxil), Baraclude (entecavir), Tyzeka (telbivudine), and Viread (tenofovir) are available on Coventry s prescription drug coverage and do not require a prior authorization. NON-COVERAGE: 1. Use not approved by the FDA; and 2. The use is unapproved and not supported by the literature or evidence as an accepted off-label use. (see Off-Label Use Policy for determining accepted use )
3 Appendix I: Treatment Algorithm for Chronic Hepatitis B with HBeAg + HBeAg + Detectable HBsAg > 6 months HBV DNA 10 5 c/ml or 20,000 IU/ml(PCR) HBV DNA < 10 5 c/ml or <20,000 IU/ml (PCR) Treatment Monitor every 6-12 months rmal ALT ( 2 x ULN) Biopsy, if >40 yrs, ALT persistently high normal (2xULN), or with family history of HCC Treatment, if biopsy shows moderate/severe inflammation or significant fibrosis. Low efficacy with current treatment. Observe; consider treatment when ALT becomes elevated. Elevated ALT (>2 x ULN) Treat with either one of the following: IFN-α Nucleoside Analogs (NA) Intron A (standard) (for 16 Weeks) Pegasys (pegylated) (for 48 Weeks) Epivir- HBV** (1 year) Hepsera Viread Baraclude Tyzeka** HBV DNA 2 Log 10 Drop (Continue treatment) HBV DNA <2 Log 10 Drop alternative NA. End Point: Seroconversion from HBeAg to Anti-HBe. For treatment with NA, complete at least 6 months of additional treatment after appearance of Anti-HBe. ** t recommended due to high rate of drug resistance.
4 Appendix II: Treatment Algorithm for Chronic Hepatitis B with HBeAg - HBeAg - Detectable HBsAg > 6 months HBV DNA 10 5 c/ml or 20,000 IU/ml(PCR) Elevated ALT (>2 x ULN) HBV DNA > 10 4 c/ml or >2000 IU/ml (PCR) rmal ALT (1-2 x ULN) HBV DNA < 10 4 c/ml or <2000 IU/ml (PCR) ALT ULN Consider liver biopsy. Treatment, if biopsy shows moderate/severe inflammation or significant fibrosis. Observe; treat if HBV DNA or ALT becomes higher. Treat with either one of the following: IFN-α Nucleoside Analogs (NA) Intron A (standard) (1 year) Pegasys (pegylated) (1 year) Epivir- HBV** (>1 year) Hepsera (>1 Year) Viread Baraclude (>1 Year) Tyzeka** (>1 Year) HBV DNA 2 Log 10 Drop (Continue treatment) HBV DNA <2 Log 10 Drop alternative NA. End Point: Sustained rmalization of ALT and Undetectable HBV DNA by PCR Assay ** t recommended due to high rate of drug resistance.
5 Appendix III: Treatment Algorithm for Chronic Hepatitis B with Cirrhosis HBeAg +/- HBV DNA (PCR) Detectable HBV DNA (PCR) Undetectable Compensated Decompensated Compensated Decompensated HBV DNA < 2000 IU/ml HBV DNA > 2000 IU/ml Observe Refer for Liver Transplant Consider treatment if ALT elevated (ALT > 2x ULN) Coordinate treatment with transplant center. Treatment should be promptly initiated with a NA that can produce rapid viral suppression with low risk of drug resistance. Epivir-HBV (or Tyzeka) + Hepsera or Baraclude Life-long treatment is recommended. IFN-α (standard or pegylated) should not be used. Lifelong treatment recommended if recurrent hepatitis B post-liver transplantation. Treatment with NA-- Epivir-HBV**, Hepsera, Tyzeka**, Viread, or Baraclude as initial therapy. Patients should receive long-term treatment; may stop in HBeAg+ patients if confirmed HBeAg seroconversion and have completed at least 6 months of consolidation therapy; may stop in HBeAg- patients if confirmed HBsAg clearance. IFN-α use associated with flares of hepatitis and risk of hepatic decompensation. ** t recommended due to high rate of drug resistance.
6 REFERENCES: 1. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12): Lok ASF, McMahon B. Chronic hepatitis B. Hepatology 2001; 34: Hepatitis B Foundation. Available at: Accessed: January Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigennegative chronic hepatitis B. Gastroenterology 2001;121: Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001;34: Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 summary of a workshop. Gastroenterology 2001;120: Roche Laboratories Inc. Pegasys (peginterferon alfa 2a). Prescribing Information. Nutley, NJ: Roche; May Bristol-Myers Squibb Company. Baraclude (entecavir). Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; March GlaxoSmithKline. Epivir-HBV (lamivudine). Prescribing Information. Research Triangle Park, NC. GlaxoSmithKline; December Gilead Sciences, Inc.Viread (tenofovir). Prescribing Information. Gilead Sciences; October Gilead Sciences, Inc. Hepsera (Adefovir dipivoxil). Prescribing Information. Gilead Sciences; August Schering Corporation. Intron A (interferon alfa 2b). Prescribing Information. Kenilworth, NJ: Schering Corporation; March Keeffe EB, Dieterich DT, Han SHB, et al. A Treatment Algorithm for the Management of Chronic Hepatitis B Infection in the United States. Clinical Gastroenterology and Hepatology 2004;2: Lok ASF, McMahon BJ, Practice Guidelines Committee: American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39: vartis. Tyzeka (telbivudine). Prescribing Information. vartis; October Lok ASF, McMahon BJ. American Association for the Study of Liver Diseases (AASLD) Practice guidelines: Chronic hepatitis B. Hepatology. Feb, : Loki AS, McMahon BJ. AASLD Practice Guideline: Chronic Hepatitis B: Update Hepatology 2009; 50(3):1-36. DISCLAIMER: Coventry Health Care, Inc. (CHC) medical policies, technology assessments, and medical reviews (collectively CHC Policies ) are developed by CHC to provide guidance in administering plan benefits and constitute neither offers of coverage nor medical advice. Access to CHC Policies is provided for general reference purposes only and does not infer guaranteed coverage. CHC does not provide health care services or supplies. Providers are expected to exercise their independent medical judgment in rendering the most appropriate care. State and federal law, as well as health plan policy terms and conditions and CHC Policies in effect on the date that any service is rendered, including but not limited to definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for CHC Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determination (NCD), Local Medical Review Policies (LMRP), and/or Local Coverage Determinations (LCD). As clinical technology is continually updated, CHC policies are subject to periodic updates. Do not rely on printed versions of CHC policies as they may be outdated. part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or means without the written consent of CHC. Dec 2010
Treatment of Hepatitis B
Treatment of Hepatitis B Paul Y Kwo, MD Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of Medicine
More informationVirology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H
Virology Behandlung der Hepatitis B Markus Heim Universitätsspital Basel 1 2 HBV Genome HBV life cycle 3 4 HBV Genotypes Natural History 8 genotypes: A, B, C, D, E, F, G, H genotypes A and D are prevalent
More informationHBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine
HBV Treatment Guidelines By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine A 29 Y old lady diagnosed as chronic HBV 3 years ago during her pregnancy, no treatment
More informationManagement of Chronic Hepatitis B: 2012 Update
Management of Chronic Hepatitis B: 2012 Update Brian J McMahon MD, Liver Disease and Hepatitis Program Alaska Native Medical Center and Arctic Investigations Program, CDC Conflicts of Interest The Liver
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationThe availability of newer antiviral agents, as
TREATMENT OF HEPATITIS B VIRUS INFECTION * Norman L. Sussman, MD ABSTRACT In treating chronic hepatitis B virus (HBV) infection, the primary goal of therapy is to achieve sustained suppression of HBV replication,
More informationSafety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationTreatment Strategies of Hepatitis B in China
Treatment Strategies of Hepatitis B in China Guangbi Yao MD Shanghai Jing-An Qu Central Hospital 200040 Characteristic features of CHB in China Huge amount of patients Infection during early life Maternal
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More informationChronic hepatitis B (CHB) remains an important public SPECIAL REPORT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1315 1341 SPECIAL REPORT A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update EMMET B. KEEFFE,*
More informationThe Natural History of Chronic Hepatitis B Virus Infection
The Natural History of Chronic Hepatitis B Virus Infection Brian J. McMahon, M.D. 1 ABSTRACT Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic
More informationAASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents
More informationStepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection
Stepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection Federal Bureau of Prisons Clinical Practice Guidelines January 20, 2011 Clinical guidelines are made available
More informationAASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines
More informationCASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA
CASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA Characteristics of HBV DNA Hepadnavirus Reverse transcriptase
More informationUpdate on Pharmacotherapy of Chronic Hepatitis B and C
Update on Pharmacotherapy of Chronic Hepatitis B and C Rebecca L. Corey, Pharm.D., BCPS Reviewed by Paulina Deming, B.S., Pharm.D., PhC; Lisa C. Hutchison, Pharm.D., MPH, FCCP, BCPS; and Hannah R. Howell,
More informationIn the last decade, important advances have been made
REVIEW Management of Hepatitis B: Summary of a Clinical Research Workshop Jay H. Hoofnagle, 1 Edward Doo, 1 T. Jake Liang, 2 Russell Fleischer, 3 and Anna S.F. Lok 4 Chronic hepatitis B is caused by persistent
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Pegasys and non-preferred Hepatitis C Agents must
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationHepatitis B: Diagnosis and Treatment
: Diagnosis and Treatment THAD WILKINS, MD; DAVE ZIMMERMAN, MD; and ROBERT R. SCHADE, MD Medical College of Georgia, Augusta, Georgia Although an estimated 1 million persons in the United States are chronically
More informationManagement of Chronic Hepatitis B: Consensus Guidelines
Management of Chronic Hepatitis B: Consensus Guidelines Morris Sherman MD PhD 1, Stephen Shafran MD 2, Kelly Burak MD 3, Karen Doucette MD 2, Winnie Wong MD 2, Nigel Girgrah MD 1, Eric Yoshida MD 4, Eberhard
More informationMonth/Year of Review: March 2014 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationTreatment Options for Children with Hepatitis B
Treatment Options for Children with Hepatitis B Special thanks to Philip Rosenthal, MD, for reviewing this document. Updated summer 2010 When given the news that their child has chronic hepatitis B, the
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationAASLD PRACTICE GUIDELINES Chronic Hepatitis B
AASLD PRACTICE GUIDELINES Chronic Hepatitis B Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents the position
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationEASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version)
Journal of Hepatology 38 (2003) 533 540 Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) The EASL Jury*
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B
Journal of Hepatology 50 (2009) 227 242 www.elsevier.com/locate/jhep EASL Clinical Practice Guidelines: Management of chronic hepatitis B European Association for the Study of the Liver * Keywords: Hepatitis
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More information1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;
Anti-Infective Subcommittee of PTAC Meeting held 1 March 2012 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationHow To Treat Hepatitis B With Entecavir
Management of Patients with Viral Hepatitis, Paris, 2004 New Nucleoside Analogs for the Treatment of Chronic Hepatitis B Maria Buti, Rafael Esteban Three agents have been approved for the treatment of
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationHBV screening and management in HIV-infected children and adolescents
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
More informationOptimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Liver International ISSN 1478-3223 REVIEW ARTICLE Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? Jorg Petersen 1 and Maura Dandri 2 1 IFI Institute at the Asklepios Klinik
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationHBsAg level and hepatitis B viral load correlation with focus on pregnancy
ORIGINAL ARTICLE Annals of Gastroenterology (2015) 28, 1-6 HBsAg level and hepatitis B viral load correlation with focus on pregnancy Maria Belopolskaya a, Viktor Avrutin b, Sergey Firsov a, Alexey Yakovlev
More information1. A 19 year old Caucasian male is referred to you because he recently developed acute HBV.
VIRAL HEPATITIS TEST QUESTIONS AND ANSWERS 1. A 19 year old Caucasian male is referred to you because he recently developed acute HBV. At the time of diagnosis he was HB surface antigen positive, anti-hb
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationCANADIAN CONSENSUS GUIDELINES. Management of chronic hepatitis B: Consensus guidelines
CANADIAN CONSENSUS GUIDELINES Management of chronic hepatitis B: Consensus guidelines Morris Sherman MD PhD 1, Stephen Shafran MD 2, Kelly Burak MD 3, Karen Doucette MD 2, Winnie Wong MD 2, Nigel Girgrah
More informationCANADIAN CONSENSUS GUIDELINES. Management of chronic hepatitis B: Consensus guidelines
CANADIAN CONSENSUS GUIDELINES Management of chronic hepatitis B: Consensus guidelines Morris Sherman MD PhD 1, Stephen Shafran MD 2, Kelly Burak MD 3, Karen Doucette MD 2, Winnie Wong MD 2, Nigel Girgrah
More informationDr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014
Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor Hepatology-2014 Other virus hepatitis Epstein-Barr vírus Cytomegalo vírus Herpes simplex vírus Coxsackie vírus Hepatitis B vírus Hepadnavírus,
More informationFollow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review George V. Papatheodoridis 1,, Spilios Manolakopoulos 1,
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Hepatitis C Agents that meet any of the following
More informationInfection with the hepatitis B virus
Obstetrics Report Chronic Hepatitis B in Pregnancy A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 1 Joseph Apuzzio, MD; Joan M. Block, RN, BSN; Samuel Cullison, MD; Chari
More informationThere are estimated to be more than 2 billion people REVIEW. Chronic Hepatitis B: Current Testing Strategies
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:666 676 REVIEW Chronic Hepatitis B: Current Testing Strategies ROBERT G. GISH*,, and STEPHEN A. LOCARNINI *Division of Hepatology and Complex GI, Physician
More informationPhase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Application of HBs quantification
Clinical Application of HBs quantification Hepatology on the Nile 2 Advances in Liver Disease 2014, "World Expert Review» Wednesday, September 24, 2014 Pr Tarik Asselah MD, PhD; Service d Hépatologie &
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationInfection with the hepatitis B virus
Obstetrics Report Chronic Hepatitis B in Pregnancy A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 1 Joseph Apuzzio, MD; Joan M. Block, RN, BSN; Samuel Cullison, MD; Chari
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Hepatitis C Agents A. Prescriptions That Require Prior Authorization Prescriptions for Interferon,
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationHepatitis B Virus Program
Hepatitis B Virus Program Abstract Hepatitis B is a viral hepatitis representing a major global health problem. According to the World Health Organization (WHO), some 360 million people, or 5% of the world
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationAdefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B. Issue date: February 2006
Issue date: February 2006 Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic Understanding NICE guidance information for people with chronic, their families and carers, and the public
More informationPrediction of Response to Immune Modifying Therapy for Patients with Chronic Hepatitis B using Hepatitis B Surface Antigen Levels. Vincent Rijckborst
Prediction of Response to Immune Modifying Therapy for Patients with Chronic Hepatitis B using Hepatitis B Surface Antigen Levels Vincent Rijckborst Colofon ISBN: 978-94-6169-083-8 V. Rijckborst, The Netherlands,
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationHEPATITIS B VIRUS II. HEPATITIS B VIRUS RECOMMENDATIONS:
HEPATITIS B VIRUS II. HEPATITIS B VIRUS Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis worldwide. In the United States, approximately 250,000 to 300,000 new HBV infections occur
More informationHIV and Hepatitis B CoInfection
HIV and Hepatitis B CoInfection Douglas G. Fish, MD June 3, 2014 44 yo male with AIDS who had fallen out of care and returned in October 2013 Last seen in November 2012 CD4 at that time 340 cells/cmm HIV
More informationDiagnosi e terapia delle epatiti croniche virali
Diagnosi e terapia delle epatiti croniche virali Fabrizio Magnolfi Direttore della Struttura Complessa di Gastroenterologia Ospedale S. Donato - Arezzo Caso clinico 1 Fattori eziologici delle Epatopatie
More informationHEPATITIS C TREATMENT GUIDELINES
HEPATITIS C TREATMENT GUIDELINES Updated May 21, 2014 INSTRUCTIONS: 1. Review the posted Hepatitis C Treatment Guidelines document to validate that your patient meets the criteria for treatment. 2. Complete
More informationHBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years Massimo Fasano 1, Pietro Lampertico 2, Alfredo Marzano 3, Vito Di Marco 4,
More informationGUIDELINE. South African guideline for the management of chronic hepatitis B: 2013
South African guideline for the management of chronic hepatitis B: 2013 C W N Spearman, 1 MB ChB, FCP (SA), MMed, PhD; M W Sonderup, 1,2 MB ChB, BPharm, FCP (SA); J F Botha, 2,3 MB ChB, FCP (SA); S W van
More informationHepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs
Last update: February 23, 2015 Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs Please see healthpartners.com for Medicare coverage criteria. Table of Contents 1. Harvoni 2. Sovaldi
More informationScottish Medicines Consortium
Scottish Medicines Consortium peginterferon alfa-2a, 135 microgram/ml and 180 microgram/ml pre-filled injections of solution for subcutaneous injection (Pegasys ) No. (561/09) Roche Products Limited 10
More informationChronic Hepatitis B (CHB) Recommendations
Clinical update Australian and New Zealand Chronic Hepatitis B (CHB) Recommendations 1st Edition 2008 Digestive Health Foundation 2008 Digestive Health Foundation Table of contents CHAPTER PAGE 1. Chronic
More informationProlonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study.
Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study. Heiner Wedemeyer*, Cihan Yurdaydın*, Stefanie Ernst, Florin
More informationTreatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011
CLINICAL GUIDELINES DANISH MEDICAL JOURNAL Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011 Peer Brehm Christensen, Mette Rye Clausen, Henrik
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationDIAGNOSING DIFFERENT STAGES OF HEPATITIS B INFECTION USING A COMPETITIVE POLYMERASE CHAIN REACTION ASSAY
Indian Journal of Medical Microbiology, (2008) 26(2): 138-42 Original Article DIAGNOSING DIFFERENT STAGES OF HEPATITIS B INFECTION USING A COMPETITIVE POLYMERASE CHAIN REACTION ASSAY H Changotra, A Dwivedi,
More informationCOPYRIGHT PULSUS SpeCiAL GROUP ArtiCLe DO NOT COPY
COPYRIGHT PULSUS SpeCiAL GROUP ArtiCLe DO NOT COPY Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Carla S Coffin MD MSc, FRCPC 1, Scott K Fung MD
More informationLiver Wellness Increasing Public Awareness of Liver Health
Liver Wellness Increasing Public Awareness of Liver Health Managing Your Medications Managing Your Medications Medicines can help you feel better and keep you feeling well, but they can be hard to manage.
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationSupplementary Online Content
Supplementary Online Content Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving
More informationHepatitis B reactivation. Geoffrey Dusheiko UCL Institute for Liver and Digestive Health Royal Free Hospital London, UK
Hepatitis B reactivation Geoffrey Dusheiko UCL Institute for Liver and Digestive Health Royal Free Hospital London, UK HBV reactivation Defined as abrupt rise in HBV replication (> 1 log) Followed by lab
More information2015 Outpatient Chronic Hepatitis B Management
2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis
More informationLiver Disease and Therapy of Hepatitis B Virus Infections
Liver Disease and Therapy of Hepatitis B Virus Infections University of Adelaide Catherine Scougall Arend Grosse Huey-Chi Low Allison Jilbert Fox Chase Cancer Center Chunxiao Xu Carol Aldrich Sam Litwin
More information8/12/14 HEPATITIS B. Chronische hepatitis B en C. Epidemiologie Besmetting Natuurlijke evolutie Symptomen Diagnose Behandeling. Overzicht.
Chronische hepatitis B en C. 1 dec 214 Prof. Dr. Hendrik Reynaert MD, PhD Dienst gastroenterologie-hepatologie UZBrussel Fysiologie VUB Overzicht Epidemiologie Besmetting Natuurlijke evolutie Symptomen
More informationPhysician s Guide to. Hepatitis B. a silent killer. Developed by the Asian Liver Center at Stanford University
2013 Physician s Guide to Hepatitis B a silent killer Developed by the Asian Liver Center at Stanford University Table of Contents Recommended Tests to Screen for Chronic Hepatitis B 2 HBV and Liver Cancer
More informationHepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable.
Two Silent Epidemics - Chronic Hepatitis B and Hepatitis C: A Primer for Primary Care Practitioners Rebekah Hamner, MA, MSN, APRN, AGCNS Austin Hepatitis Center Dr. Imtiaz Alam 1/25/15 Hepatitis B: Objectives
More informationThe natural history of chronic HBV infection
Hepatitis B Viral Factors in HBeAg-Negative Carriers with Persistently Normal Serum Alanine Aminotransferase Levels Chih-Lin Lin, 1* Li-Ying Liao, 1* Chun-Jen Liu, 2 Ming-Whei Yu, 3 Pei-Jer Chen, 2,4 Ming-Yang
More informationFuture Challenges in Hepatitis B Treatment. Maria Buti Hospital Universitario Valle Hebron Barcelona
Future Challenges in Hepatitis B Treatment Maria Buti Hospital Universitario Valle Hebron Barcelona Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck
More informationWhen an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)
XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission
More informationBriefing Note: Hepatitis B & Hepatitis C. Summary:
Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and
More informationRibavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C
Ribavirin/Pegylated Combination Therapy for People with Hepatitis C 1. Introduction 2. What the treatment does 3. When to take it 4. What is? 5. What is interferon? 6. What is pegylated interferon? 7.
More informationHCV treatment today: pegylated interferons and ribavirin
HCV treatment today: pegylated interferons and ribavirin Other special patient populations Patients with cirrhosis Higher SVR rates are achieved in patients without cirrhosis Patients without bridging
More informationReview Article Treatment of Hepatitis B in Decompensated Liver Cirrhosis
SAGE-Hindawi Access to Research International Journal of Hepatology Volume 2011, Article ID 918017, 11 pages doi:10.4061/2011/918017 Review Article Treatment of Hepatitis B in Decompensated Liver Cirrhosis
More informationIT IS ESTIMATED that there are 400 million patients of
bs_bs_banner Hepatology Research 2014; 44 (Suppl. 1): 1 58 doi: 10.1111/hepr.12269 Special Report JSH Guidelines for the Management of Hepatitis B Virus Infection Drafting Committee for Hepatitis Management
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More information